Nanoparticles for Cancer Drug Delivery

Leuschner, Carola; Kumar, Challa S. S. R.

doi:10.1002/3527603476.ch11

Cited by 7 publications

(4 citation statements)

References 137 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the formulations, nP1 and nP2 had the average hydrodynamic size of around 100 nm (figure 6). The expansion in the size of the nanoparticles obtained by DLS compared to FeSEM method can be accounted by the hydrophilic interaction of PVP molecules as similarly reported elsewhere [31]. The nP1 and nP2 formulations were stable with the zeta potential of −20.9 and −24.1 mV, respectively.…”

Section: Nanoformulationssupporting

confidence: 71%

Platinum (II) complexes and their nanoformulations: preparation, characterisation and cytotoxicity

Phan¹,

Le²,

Phan³

et al. 2021

Adv. Nat. Sci: Nanosci. Nanotechnol.

View full text Add to dashboard Cite

Development of novel drugs or drug delivery systems has attracted much attention of researchers. In this study, we aimed to prepare 2 new Pt(II) complexes with thiosemicarbazone and their nanoformulations for cancer treatment application. Pt(II)-camphor thiosemicarbazone/ P1 and Pt(II)-camphor 4-phenyl thiosemicarbazone/P2) were successfully prepared and structurally confirmed by MS, IR, 1H-NMR, UV-vis spectroscopies and thermal analysis. From the complexes, 2 PLGA-based nanoformulations (nP1 and nP2) were synthesised with the average size of 50 nm by emulsification/evaporation method and investigated for their toxicity against Hep-G2, LU-1 and RD cancer cell lines. The results show that the Pt(II) complexes and their nanoformulations were potential for chemotherapy.

show abstract

Section: Nanoformulationssupporting

confidence: 71%

Platinum (II) complexes and their nanoformulations: preparation, characterisation and cytotoxicity

Phan¹,

Le²,

Phan³

et al. 2021

Adv. Nat. Sci: Nanosci. Nanotechnol.

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown size-dependent tumor-specific delivery of nano- particles to the tumor microvasculator through the enhanced permeation and retention (EPR) effect. 41,42 We found that increasing the size of the nanoparticle from d ) 90 ( 10 nm to d ) 350 ( 50 nm resulted in enhanced preferential cytotoxicity for tumor versus nontumor ovarian cells. Although our initial studies were done in Vitro, with evaluation of only two normal immortalized cell lines and their transformed isogenic counterparts, we believe that these observations are quite significant.…”

Section: Discussionmentioning

confidence: 92%

Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth

et al. 2010

View full text Add to dashboard Cite

Although the potent anti-tumor activity of nitric oxide (NO) supports its promise as an anti-neoplastic agent, effective and selective delivery and action on tumor and not normal cells remains a limiting factor. Nanoparticle-based delivery of NO has been considered as one approach to overcome these limitations. Therefore, we determined the utility of NO delivery using silica nanoparticles and evaluated their anti-tumor efficacy against human ovarian tumor and nontumor cells. The NO-releasing nanoparticles exhibited enhanced growth inhibition of ovarian tumor cells when compared to both control nanoparticles and a previously reported small molecule NO donor, PYRRO/NO. In addition, the NO-releasing nanoparticles showed greater inhibition of the anchorage-independent growth of tumor-derived and Ras-transformed ovarian cells. Confocal microscopy analysis revealed that fluorescently-labeled NO-releasing nanoparticles entered the cytosol of the cell and localized to late endosomes and lysosomes. Furthermore, we observed a nanoparticle size dependency on efficacy against normal versus transformed ovarian cells. Our study provides the first application of nanoparticle-derived NO as an antitumor therapy and supports the merit for future studies examining nanoparticle formulation for in vivo applications.

show abstract

“…Recently, nanomaterials have effectively been employed to deliver biologically active cargo into living systems for the purposes of disease diagnosis and therapy. , Among diverse classes of nanomaterials, carbon nanotubes (CNTs) have attracted particular attention as carriers of biologically relevant molecules due to their unique physical, chemical, and physiological properties. − It has been shown, for example, that CNTs can serve as a highly efficient vehicle to transport a wide range of molecules across membranes into living cells. − In addition, the intrinsic stability and structural flexibility of CNTs may prolong the circulation time as well as the bioavailability of drug molecules conjugated to CNTs. − Radiolabeled functionalized SWNTs ( f -SWNTs) have been found to exhibit a blood circulation half-life of 1−3 h, depending on the radiolabels used. , For instance, [ 111 In]- f -SWNTs exhibited a slightly longer blood circulation half-life as compared with [ 86 Y]- f -SWNTs . When SWNTs were noncovalently wrapped with a linear poly(ethylene glycol) (PEG) chain, the blood circulation time of the PEG-SWNT was prolonged with increasing molecular weight of the PEG chain, e.g., from 1.2 h for 2 kDa PEG-wrapped SWNTs to 5 h for 5 kDa PEG-wrapped SWNTs .…”

Section: Introductionmentioning

confidence: 99%

Functionalized Single-Walled Carbon Nanotubes as Rationally Designed Vehicles for Tumor-Targeted Drug Delivery

et al. 2008

View full text Add to dashboard Cite

A novel single-walled carbon nanotube (SWNT)-based tumor-targeted drug delivery system (DDS) has been developed, which consists of a functionalized SWNT linked to tumor-targeting modules as well as prodrug modules. There are three key features of this nanoscale DDS: (a) use of functionalized SWNTs as a biocompatible platform for the delivery of therapeutic drugs or diagnostics, (b) conjugation of prodrug modules of an anticancer agent (taxoid with a cleavable linker) that is activated to its cytotoxic form inside the tumor cells upon internalization and in situ drug release, and (c) attachment of tumor-recognition modules (biotin and a spacer) to the nanotube surface. To prove the efficacy of this DDS, three fluorescent and fluorogenic molecular probes were designed, synthesized, characterized and subjected to the analysis of the receptor-mediated endocytosis and drug release inside the cancer cells (L1210FR leukemia cell line) by means of confocal fluorescence microscopy. The specificity and cytotoxicity of the conjugate have also been assessed and compared with L1210 and human non-cancerous cell lines. Then, it has unambiguously been proven that this tumor-targeting DDS works exactly as designed and shows high potency towards specific cancer cell lines, thereby forming a solid foundation for further development.

show abstract

Nanoparticles for Cancer Drug Delivery

Cited by 7 publications

References 137 publications

Platinum (II) complexes and their nanoformulations: preparation, characterisation and cytotoxicity

Platinum (II) complexes and their nanoformulations: preparation, characterisation and cytotoxicity

Nitric Oxide-Releasing Silica Nanoparticle Inhibition of Ovarian Cancer Cell Growth

Functionalized Single-Walled Carbon Nanotubes as Rationally Designed Vehicles for Tumor-Targeted Drug Delivery

Contact Info

Product

Resources

About